Dublin, May 15, 2025 (GLOBE NEWSWIRE) -- The "Cyramza (Ramucirumab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to ResearchAndMarkets.com's offering.
This Cyramza (Ramucirumab) market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Cyramza (ramucirumab) is a monoclonal antibody used in cancer treatment. It works by targeting and inhibiting the vascular endothelial growth factor receptor 2 (VEGFR-2), which helps prevent tumor blood vessel formation. Cyramza is commonly used to treat various cancers, including gastric, colorectal, and lung cancer.
The primary types of cyramza (ramucirumab) are 100mg/Box and 500mg/Box. The 100mg/Box refers to the packaging size of Cyramza, with each box containing 100 mg of the drug. This smaller packaging is typically used for patients requiring a lower dose of the medication, facilitating easier distribution and use in different medical settings. Cyramza has various applications in the treatment of advanced gastric cancer, GEJ adenocarcinoma, non-small cell lung carcinoma, metastatic colorectal cancer (MCRC), and hepatocellular carcinoma (HCC). It is utilized by end users such as hospitals, cancer treatment centers, ambulatory surgical centers, and research institutes.
The cyramza (ramucirumab) market consists of sales of cyramza (ramucirumab) iv infusion and combination therapy formulations. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The growth observed during the historical period can be attributed to factors such as the rising prevalence of colorectal cancer, increasing air pollution levels, the rising incidence of malignancies, smoking and tobacco consumption, and the growing geriatric population. Market growth during the forecast period is driven by factors such as the increase in clinical trials, the expansion of cancer screening programs, growing demand for treatment, an increasing number of patients, and changing lifestyle factors. Key trends in the forecast period include the expanding applications of ramucirumab, FDA approvals, a focus on personalized medicine, the growing adoption of combination therapies, and continuous product innovation.
The increasing incidence of cancer is expected to drive the growth of the cyramza (ramucirumab) market in the coming years. Cancer is a group of diseases marked by uncontrolled cell growth and the spread of cells to other body parts. The rise in cancer cases is due to factors like an aging population, lifestyle choices, environmental exposures, improved detection, and genetic factors. Cyramza (ramucirumab) is used in cancer treatment to target and inhibit the vascular endothelial growth factor receptor 2 (VEGFR-2), which helps prevent the growth of blood vessels that nourish tumors and slow cancer progression.
For example, according to a report by the Australian Institute of Health and Welfare published in August 2024, Australia is projected to have around 209,000 new cancer diagnoses by 2034, up from an estimated 169,000 in 2024. This increase reflects both the growing population and rising cancer rates. Furthermore, cancer is expected to account for approximately 30% of all deaths in the country by 2024. As a result, the growing incidence of cancer is driving the expansion of the cyramza (ramucirumab) market.
A key trend in the cyramza (ramucirumab) market is the development of innovative drug therapies aimed at improving treatment for patients with advanced or metastatic cancer. Drugs like ramucirumab for hepatocellular carcinoma (HCC) target specific cancer markers to slow tumor growth and improve survival rates.
Key Topics Covered:
1. Executive Summary
2. Cyramza (Ramucirumab) Market Characteristics
3. Cyramza (Ramucirumab) Market Biologic Drug Characteristics
3.1. Molecule Type
3.2. Route of Administration (ROA)
3.3. Mechanism of Action (MOA)
3.4. Safety and Efficacy
4. Cyramza (Ramucirumab) Market Trends and Strategies
5. Cyramza (Ramucirumab) Market - Macro Economic Scenario Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market
6. Global Cyramza (Ramucirumab) Growth Analysis and Strategic Analysis Framework
6.1. Global Cyramza (Ramucirumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
6.2. Analysis of End Use Industries
6.3. Global Cyramza (Ramucirumab) Market Growth Rate Analysis
6.4. Global Cyramza (Ramucirumab) Historic Market Size and Growth, 2019-2024, Value ($ Billion)
6.5. Global Cyramza (Ramucirumab) Forecast Market Size and Growth, 2024-2029, 2034F, Value ($ Billion)
6.6. Global Cyramza (Ramucirumab) Total Addressable Market (TAM)
7. Global Cyramza (Ramucirumab) Market Pricing Analysis & Forecasts
8. Cyramza (Ramucirumab) Market Segmentation
8.1. Global Cyramza (Ramucirumab) Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 100mg/Box
- 500mg/Box
8.2. Global Cyramza (Ramucirumab) Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Advanced Gastric Cancer
- GEJ Adenocarcinoma
- Non-small Cell Lung Carcinoma
- Metastatic Colorectal Cancer (mCRC)
- Hepatocellular Carcinoma (HCC)
8.3. Global Cyramza (Ramucirumab) Market, Segmentation by End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Cancer Treatment Centers
- Ambulatory Surgical Centers
- Research Institutes
9. Global Cyramza (Ramucirumab) Market Epidemiology of Clinical Indications
9.1. Drug Side Effects
9.2. Incidence and Prevalence of Clinical Indications
10. Cyramza (Ramucirumab) Market Regional and Country Analysis
10.1. Global Cyramza (Ramucirumab) Market, Split by Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. Global Cyramza (Ramucirumab) Market, Split by Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
For more information about this report visit https://www.researchandmarkets.com/r/qogqyi
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
